The central role of dendritic cells and interferon-α in SLE
V Pascual, J Banchereau… - Current opinion in …, 2003 - journals.lww.com
V Pascual, J Banchereau, AK Palucka
Current opinion in rheumatology, 2003•journals.lww.comThe disease model that the authors propose places interferon-α at the center of the
immunologic abnormalities observed in systemic lupus erythematosus, and poses interferon-
α and/or interferon-α-producing cells as novel targets for therapy in this disease. The authors
surmise that type I interferon antagonists will bring systemic lupus erythematosus patients
the relief that tumor necrosis factor antagonists brought to patients with rheumatoid arthritis.
immunologic abnormalities observed in systemic lupus erythematosus, and poses interferon-
α and/or interferon-α-producing cells as novel targets for therapy in this disease. The authors
surmise that type I interferon antagonists will bring systemic lupus erythematosus patients
the relief that tumor necrosis factor antagonists brought to patients with rheumatoid arthritis.
Summary
The disease model that the authors propose places interferon-α at the center of the immunologic abnormalities observed in systemic lupus erythematosus, and poses interferon-α and/or interferon-α-producing cells as novel targets for therapy in this disease. The authors surmise that type I interferon antagonists will bring systemic lupus erythematosus patients the relief that tumor necrosis factor antagonists brought to patients with rheumatoid arthritis.
Lippincott Williams & Wilkins